ClinicalTrials.gg
CompletedNCT05133531ACCESS-1Updated Nov 6, 2026

A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment

A Phase 3 interventional study of Ravulizumab and Pozelimab in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Regeneron Pharmaceuticals. Completed at 68 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

How we know

Updated Nov 6, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals — 3 open to participants now, 3 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · Regeneron Pharmaceuticals.

Started
2022
with 1 other
Phase 3
5 of 10
2 open now
Registered
5th of 10
by date

Among the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, this one is one of 2 that started in 2022, is one of 5 in phase 3, and was the 5th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 48 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

3 of the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 29 Hemoglobinuria, Paroxysmal studies recruiting now, 13 (45%) set no upper age limit and 11 (38%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, or all of them as a file.
02

Study summary

This study is researching a clinical treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on people with paroxysmal nocturnal hemoglobinuria (PNH). The aim of the study is to see how safe and effective the pozelimab + cemdisiran combination is for people with PNH and how the combination compares with 2 existing treatments: ravulizumab and eculizumab.

The pozelimab + cemdisiran combination may be referred to as "study drugs". Ravulizumab and eculizumab may also be called the "comparator drug".

The study is looking at several research questions, including:

  • How effective is the pozelimab + cemdisiran combination compared to ravulizumab?
  • How effective is pozelimab + cemdisiran combination compared to eculizumab?
  • What side effects may happen from taking the study drugs?
  • How much study drugs are in the blood at different times?
  • Whether the body makes antibodies against the study drugs (which could make the study drugs less effective or could lead to side effects)
03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria

Keywords

  • PNH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Diagnosis of PNH confirmed by high-sensitivity flow cytometry testing with PNH granulocytes or monocytes as described in the protocol
  2. Active disease, as defined by the presence of 1 or more PNH-related signs or symptoms as described in the protocol
  3. LDH level ≥2 × at the screening visit
  4. Willing and able to comply with clinic/remote visits and study-related procedures, including completion of the full series of meningococcal vaccinations required per protocol

Key Exclusion Criteria:

  1. Prior treatment with eculizumab within 3 months prior to screening, ravulizumab within 6 months prior to screening, or other complement inhibitors within 5 half-lives of the respective agent prior to screening
  2. Receipt of an organ transplant, history of bone marrow transplantation or other hematologic transplant
  3. Body weight \<40 kilograms at screening visit
  4. Planned use of any complement inhibitor therapy other than study drugs during the treatment period
  5. Not meeting meningococcal vaccination requirements and, at a minimum documentation of quadrivalent meningococcal vaccination within 5 years prior to the screening visit and serotype B vaccine within 3 years prior to the screening visit as described in the protocol.
  6. Any for receiving Neisseria meningitidis vaccinations (serotypes ACWY and B).
  7. Unable to take antibiotics for meningococcal prophylaxis (if required by local ravulizumab [Cohort A] or eculizumab [Cohort B] prescribing information, where available, or national guidelines/local practice, or if necessary when administration of the first dose of the quadrivalent meningococcal vaccine [serotype ACWY] or the second dose of the serotype B meningococcal vaccine [when available] is less than 2 weeks prior to study treatment initiation) as described in the protocol
  8. Any active, ongoing infection or a recent infection requiring ongoing systemic treatment with antibiotics, antivirals, or antifungals within 2 weeks of screening or during the screening period
  9. Documented history of active, uncontrolled, ongoing systemic diseases

Note: Other protocol-defined Inclusion/ Exclusion Criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    Cohort A

    Randomized 1:1

    Drug: Ravulizumab · Drug: Pozelimab · Drug: Cemdisiran

  • Experimental
    Cohort B

    Randomized 1:1

    Drug: Pozelimab · Drug: Cemdisiran · Drug: Eculizumab

Interventions

  • Administered Intravenous (IV) per the protocol

    Also known as: ALXN1210, Ultomiris

  • Administered IV and subcutaneous (SC) per the protocol

    Also known as: REGN3918

  • Administered SC per the protocol

    Also known as: ALN-CC5

  • Administered IV per the protocol

    Also known as: Soliris

06

What researchers measure

Primary outcomes

  1. Percent change in lactate dehydrogenase (LDH)

    Cohort A

    Time frame: From baseline to week 26

  2. Transfusion avoidance

    Cohort B Not requiring a red blood cell (RBC) transfusion per the protocol

    Time frame: From post-baseline day 1 through week 26

  3. Adequate control of hemolysis

    Cohort B LDH ≤1.5 × ULN at each visit

    Time frame: From week 8 through week 26, inclusive

Secondary outcomes

  1. Maintenance of adequate control of hemolysis

    Cohort A and B LDH ≤1.5 × ULN

    Time frame: From week 8 through week 26, inclusive

  2. Breakthrough hemolysis

    Cohort A and B LDH ≥2 × ULN per the protocol

    Time frame: From post-baseline day 1 through week 26

  3. Adequate control of hemolysis

    Cohort A LDH ≤1.5 × ULN

    Time frame: From week 8 through week 26, inclusive

  4. Hemoglobin stabilization

    Cohort A and B Patients who do not receive an RBC transfusion and have no decrease in hemoglobin level per the protocol

    Time frame: From day 1 (post-baseline) through week 26

  5. Normalization of LDH

    Cohort A and B LDH ≤1.0 × ULN per the protocol

    Time frame: Between week 8 through week 26, inclusive

  6. Transfusion avoidance

    Cohort A and B Not requiring an RBC transfusion as per protocol algorithm based on post-baseline hemoglobin values.

    Time frame: Day 1 through week 26

  7. Change in fatigue as measured by the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale

    Cohort A and B FACIT-Fatigue Scale is a 13-item, self-reported PRO measure assessing an individual's level of fatigue during their usual daily activities over the past week. This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health-related quality of life (QoL) in patients with cancer and other chronic illnesses. The FACIT-fatigue assesses the level of fatigue using a Likert scale ranging from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue.

    Time frame: From baseline to week 26

  8. Change in physical function (PF) scores on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)

    Cohort A and B EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 7 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, sleep and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."

    Time frame: From baseline to week 26

  9. Change in global health status (GHS)/QoL scale score on the EORTC-QLC-C30

    Cohort A and B EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 7 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, sleep and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."

    Time frame: From baseline to week 26

  10. Percent change in LDH

    Cohort B

    Time frame: From baseline to week 26

  11. Rate of RBC transfused

    Cohort A and B Per protocol algorithm

    Time frame: Post-baseline Day 1 through week 26

  12. Number of units of RBC transfused

    Cohort A and B Per protocol algorithm

    Time frame: Post-baseline Day 1 through week 26

  13. Time to first LDH ≤1.5 × ULN

    Cohort A and B

    Time frame: Up to Week 26

  14. Time to first LDH ≤1.0 × ULN

    Cohort A and B

    Time frame: Up to Week 26

  15. Percentage of days with LDH ≤1.5 × ULN

    Cohort A and B

    Time frame: Between week 8 and week 26, inclusive

  16. Change in hemoglobin levels

    Cohort A and B

    Time frame: From baseline to week 26

  17. Incidence and severity of treatment emergent serious adverse events (SAEs)

    Cohort A and B

    Time frame: Up to 26 weeks

  18. Incidence and severity of treatment-emergent adverse events (TEAEs) of special interest

    Cohort A and B

    Time frame: Up to 26 weeks

  19. Incidence and severity of TEAEs leading to treatment discontinuation

    Cohort A and B

    Time frame: Up to 26 weeks

  20. Change in total CH50

    Cohort A and B

    Time frame: From baseline to week 26

  21. Percent change in total CH50

    Cohort A and B

    Time frame: From baseline to week 26

  22. Concentration of total C5 in plasma

    Cohort A and B

    Time frame: Up to 60 weeks

  23. Concentrations of total pozelimab in serum

    Cohort A and B

    Time frame: Up to 60 weeks

  24. Concentrations of cemdisiran in plasma

    Cohort A and B

    Time frame: Up to 60 weeks

  25. Concentrations of total ravulizumab in serum

    Cohort A

    Time frame: Up to 34 weeks

  26. Concentrations of total eculizumab in serum

    Cohort B

    Time frame: Up to 30 weeks

  27. Incidence of treatment emergent anti-drug antibodies (ADAs) to pozelimab

    Cohort A and B

    Time frame: Up to 60 weeks

  28. Incidence of treatment emergent ADAs to cemdisiran

    Cohort A and B

    Time frame: Up to 60 weeks

07

Study locations

68 sites
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), the legal authority to share the data, and ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Sep 2026, 49 months.

Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's 49 months is above that.

Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Sep 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2021
First posted
Nov 24, 2021
StartActual
Aug 1, 2022
Primary completionActual
Sep 28, 2026was Oct 2026
CompletionActual
Oct 29, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 6, 2026
Primary completion
Oct 12, 2026→Sep 28, 2026 (actual)
Nov 6, 2026
Study completion
Oct 26, 2026→Oct 29, 2026 (actual)
Nov 6, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionTransfusion avoidance: how it is measured was reworded
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Active, not recruiting→Completed
    Primary completion Oct 12, 2026→Sep 28, 2026 (now actual)
    Study completion Oct 26, 2026→Oct 29, 2026 (now actual)
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionTransfusion avoidance: how it is measured was reworded
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05133531
Responsible party
Sponsor
First posted
Nov 24, 2021
Start date
Aug 1, 2022
Primary completion
Sep 28, 2026
Completion
Oct 29, 2026
Last update
Nov 6, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion